DrugPatentWatch Database Preview
Aerie Pharms Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for AERIE PHARMS INC, and what generic alternatives to AERIE PHARMS INC drugs are available?
AERIE PHARMS INC has two approved drugs.
There are ten US patents protecting AERIE PHARMS INC drugs.
There are fifty patent family members on AERIE PHARMS INC drugs in eight countries and five supplementary protection certificates in five countries.
Summary for Aerie Pharms Inc
International Patents: | 50 |
US Patents: | 10 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Aerie Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 10,588,901 | Start Trial | Y | Y | Start Trial | ||
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 9,931,336 | Start Trial | Y | Y | Start Trial | ||
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 10,654,844 | Start Trial | Y | Y | Start Trial | ||
Aerie Pharms Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 10,588,901 | Start Trial | Y | Y | Start Trial | ||
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 9,415,043 | Start Trial | Y | Start Trial | |||
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 9,993,470 | Start Trial | Y | Y | Start Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aerie Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2010127330 | Start Trial |
Japan | 2016053060 | Start Trial |
Spain | 2474150 | Start Trial |
Japan | 2011529074 | Start Trial |
Japan | 5643758 | Start Trial |
Canada | 2905089 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aerie Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3053913 | 122020000016 | Germany | Start Trial | PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119 |
3053913 | 2020C/510 | Belgium | Start Trial | PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121 |
0364417 | 97C0128 | France | Start Trial | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
3053913 | 301038 | Netherlands | Start Trial | PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3053913 | 132020000000043 | Italy | Start Trial | PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.